Short answer
Assembly Biosciences Inc (ASMB) filed its fiscal 2012 10-K annual report with the SEC on Mar 18, 2013.
- Top risk flagged: FDA approval risk: second U.S. Phase III trial for VEN 307 could be required before NDA approval
Assembly Biosciences Inc FY2012 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Development-stage specialty pharmaceutical model, advancing in-licensed topical drugs for lower gastrointestinal disorders
- VEN 307 advanced into second U.S. Phase III trial, targeting NDA filing in fourth quarter 2013 or first quarter 2014
- Strategic refocus on VEN 307 after VEN 309 hemorrhoid trial failure, with VEN 309 development activities ceased
- Extended-release, twice-daily VEN 307 formulation emphasized as a lifecycle and patent-expansion strategy
- European VEN 307 Phase III enrolled 465 patients across 27 sites in 11 countries, with statistically significant pain improvement in both doses
- Eight employees and seven consultants as of February 28, 2013, reflecting an asset-light development structure
Management Discussion & Analysis
- No product revenue since inception; accumulated development-stage deficit $92.3M at December 31, 2012
- Net loss $24.8M; R&D expense $19.5M, down 22.8% from $25.3M, G&A expense $5.3M, down 38.8% from $8.7M
- Best performer VEN 307: $5.6M 2012 R&D, up from $1.9M; worst VEN 309: $13.1M R&D, down from $22.2M
- Operating cash use $21.4M; investing cash use $3,241; financing cash inflow $4.9M, including $4.2M at-the-market proceeds
- Outlook: approximately $15M to complete VEN 307 trials; no product revenue expected for at least two years, with FDA approval targeted no earlier than late 2014 or early 2015
Risk Factors
- FDA approval risk: second U.S. Phase III trial for VEN 307 could be required before NDA approval
- Foreign manufacturing exposure: all contract manufacturers located overseas, increasing shipping-delay and import-restriction risk
- Clinical concentration: failed VEN 309 Phase III trial leaves VEN 307 as the primary development focus
- Market competition: Rectiv entered anal-fissure treatment market in Q1 2012
- License dependence: S.L.A. Pharma agreement includes up to $20 million in future milestone payments
Generated from the filing text; verify against the original. How to read a 10-K
Other Assembly Biosciences Inc annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.